Etoxadrol Stats & Data

Etoxadrol is a 1,3‑dioxolane piperidine NMDA channel blocker developed as a dissociative anesthetic. In a 28‑patient surgical series, 0.75 mg/kg IV produced profound analgesia/amnesia with active airway reflexes, modest increases in blood pressure/heart rate, and tachypnea; alternating nystagmus and vivid dreams were common, with ~20% reporting unpleasant dreams that could persist up to 24 h. One overdose (4.65 mg/kg IV) caused catalepsy, amnesia, and analgesia lasting 6 days. These findings underline that use outside monitored settings is hazardous due to immobility, emesis, and aspiration risk despite nominal preservation of airway reflexes. Combination with CNS depressants (alcohol, benzodiazepines, opioids, GHB/GBL) increases risk of unconsciousness and aspiration; stimulant or MAOI co‑use may exacerbate hypertension and tachyarrhythmias. Class‑typical tolerance and cross‑tolerance with other uncompetitive NMDA antagonists can emerge quickly; spacing exposures reduces cumulative cognitive disturbance. Identity/adulteration risk is high in any unregulated context; reagent kits are insufficient to confirm this scaffold—only instrumental analysis (e.g., GC‑MS/HR‑LC‑MS) can verify identity and detect potent adulterants. Psychological emergence reactions (agitation, dysphoria, nightmares) benefit from a quiet, low‑stimulation environment; in medical settings, sedatives or antipsychotics are used by clinicians when indicated. Due to lack of modern human pharmacokinetics, any non‑medical exposure warrants conservative observation for delayed confusion or ataxia and avoidance of hazardous activities for 24 h.